DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+15.27%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.01B
AUM Growth
+$5.01B
(+5.5%)
Cap. Flow
-$211M
Cap. Flow
% of AUM
-4.22%
Top 10 Holdings %
Top 10 Hldgs %
37.68%
Holding
145
New
16
Increased
15
Reduced
22
Closed
11
Top Buys
| 1 |
Biogen
BIIB
|
$88.1M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
$62.8M |
| 3 |
Revolution Medicines
RVMD
|
$39.4M |
| 4 |
Larimar Therapeutics
LRMR
|
$35.6M |
| 5 |
Phathom Pharmaceuticals
PHAT
|
$26.8M |
Top Sells
| 1 |
Viatris
VTRS
|
$85.2M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$69.6M |
| 3 |
AdaptHealth
AHCO
|
$55M |
| 4 |
Neurocrine Biosciences
NBIX
|
$53.1M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$49.7M |
Sector Composition
| 1 | Healthcare | 53.67% |
| 2 | Financials | 1.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $376M | 7.48% | 19,341,024 | – | – |
|
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $161M | 3.2% | 1,512,714 -500,000 | -25% | -$53.1M |
|
|
3
AdaptHealth
AHCO
$1.28B
| $154M | 3.07% | 8,223,536 -2,927,261 | -26% | -$55M |
|
|
SILK
4
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $114M | 2.27% | 2,535,369 -141,522 | -5% | -$6.37M |
|
|
CMAX
5
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $112M | 2.24% | 15,861,090 | – | – |
|
6
Gilead Sciences
GILD
$140B
| $94.9M | 1.89% | 1,537,539 -15,100 | -1% | -$932K |
|
|
7
Viatris
VTRS
$12.3B
| $90.9M | 1.81% | 10,673,700 -10,000,000 | -48% | -$85.2M |
|
|
8
Biogen
BIIB
$19.4B
| $88.1M | 1.75% | +330,000 | New | +$88.1M |
|
|
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $76.1M | 1.52% | 4,244,098 -969,902 | -19% | -$17.4M |
|
|
AERI
10
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $73.5M | 1.46% | 4,855,005 +159,985 | +3% | +$2.42M |
|
|
IMGN
11
DELISTED
Immunogen Inc
IMGN
| $65.7M | 1.31% | 13,740,205 -1,280,285 | -9% | -$6.12M |
|
|
12
Catalyst Pharmaceutical
CPRX
$2.52B
| $62.8M | 1.25% | +4,896,000 | New | +$62.8M |
|
13
Pulmonx
LUNG
$69.7M
| $62M | 1.23% | 3,720,901 +255,000 | +7% | +$4.25M |
|
|
14
Revolution Medicines
RVMD
$7.1B
| $57M | 1.14% | 2,891,587 +2,000,000 | +224% | +$39.4M |
|
|
15
Larimar Therapeutics
LRMR
$310M
| $54.2M | 1.08% | 16,941,357 +11,111,108 | +191% | +$35.6M |
|
16
Merus
MRUS
$4.98B
| $50.5M | 1.01% | 2,521,553 +535,629 | +27% | +$10.7M |
|
|
DCPH
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $46.1M | 0.92% | 2,491,490 -3,759,474 | -60% | -$69.6M |
|
18
HilleVax
HLVX
$105M
| $45.3M | 0.9% | 2,653,231 +35,283 | +1% | +$603K |
|
19
Cogent Biosciences
COGT
$1.69B
| $44.3M | 0.88% | 2,966,345 -2,910,460 | -50% | -$43.4M |
|
20
Evolus
EOLS
$494M
| $43.4M | 0.86% | 5,390,103 +1,757,352 | +48% | +$14.1M |
|
21
Mirum Pharmaceuticals
MIRM
$3.71B
| $42.7M | 0.85% | 2,032,335 -1,212,099 | -37% | -$25.5M |
|
22
Cytokinetics
CYTK
$4.23B
| $39.4M | 0.78% | 813,112 -347,203 | -30% | -$16.8M |
|
23
Edgewise Therapeutics
EWTX
$1.51B
| $38.7M | 0.77% | 3,933,137 | – | – |
|
24
AnaptysBio
ANAB
$569M
| $37.4M | 0.74% | 1,466,600 +694,600 | +90% | +$17.7M |
|
25
Brookdale Senior Living
BKD
$1.83B
| $37.1M | 0.74% | 8,692,561 +100,100 | +1% | +$427K |
|